Todd Zavodnick, Dermavant CEO

Der­ma­van­t's Vta­ma works again in eczema as Roivant sub­sidiary seeks la­bel ex­pan­sion next year

Al­most a year to the day af­ter Der­ma­vant Sci­ences land­ed its first FDA ap­proval for plaque pso­ri­a­sis for Vta­ma, the drug­mak­er is out with its sec­ond suc­cess­ful Phase III tri­al of the top­i­cal cream for treat­ing eczema.

The Roivant sub­sidiary said the steroid-free, van­ish­ing cream worked again in a late-stage study iden­ti­cal to the first, which read out in March. With da­ta from a lit­tle more than 800 pa­tients across the two stud­ies, dubbed ADOR­ING 1 and 2, the com­pa­ny plans to ask the FDA for a la­bel ex­pan­sion in atopic der­mati­tis for adults and kids as young as age 2 in the first quar­ter of 2024.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.